Trial Profile
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYMPHONY-1
- Sponsors Epizyme
- 22 Mar 2024 Planned number of patients changed from 540 to 568.
- 12 Dec 2023 Results comparing the efficacy results of the SYMPHONY-1 Phase 1b single arm trial with an external control arm (ECA) derived from the Flatiron Health Research Database (FHRD), consisting of real-world FL patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Updated efficacy and safety results (N=44) after a median follow-up of 22.5 months presented at the 65th American Society of Hematology Annual Meeting and Exposition